Head-to-head · free

TransMedics Group, Inc. vs First Tracks Biotherapeutics Inc

TMDX vs TRAX — return on capital, cash generation, margins and balance sheet side by side.

TMDX

2 / 2

measures where TMDX leads

TRAX

0 / 2

measures where TRAX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTMDX · FY2025TRAX
Revenue$605.5M—
Net income$190.3M—
Revenue growth (yearly, multi-year)111.5%—
Free cash flow$133.6M—
Free cash flow margin22.1%—
Net cash / (debt)——
ROIC——
Return on equity54.2%-40.9%
Gross margin59.9%—
Operating margin17.9%—
Net debt / EBITDA0.18x0.69x

Figures are as reported by each company; latest fiscal year shown.

Where TransMedics Group, Inc.'s cash went (FY2025)

Capital spending
$59.3M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TMDX profile →

Where First Tracks Biotherapeutics Inc's cash went

Not reported yet.

Full TRAX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons